-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Zai Lab/Deciphera Pharmaceuticals' application for the import of category 5.
Gastrointestinal stromal tumor (GIST) is a rare gastrointestinal tumor that originates from interstitial cells of Cajal, but it ranks first in soft tissue sarcoma of the gastrointestinal tract and can occur in any gastrointestinal tract.
Currently, surgery is the only cure for limited or potentially resectable GIST.
Ripretinib is a drug introduced by Zai Lab from Deciphera in 2019.
Qinlock's approval is based on the positive results of the Phase III study INVICTUS.
The results showed that compared with placebo, the progression-free survival of patients in the repetinib treatment group was significantly prolonged (mPFS was 6.
In addition to the fourth-line treatment of GIST, Peritinib is currently undergoing a Phase III study of the second-line treatment of GIST.